CDK1 and laryngeal carcinoma: lncRNA FLJ20021 is highly expressed in cisplatin-resistant laryngeal cancer cells, and silencing lncRNA FLJ20021 plays a positive role in overcoming cisplatin-resistant laryngeal cancer by regulating CDK1 and mediating PANoptosis in a ZBP1-dependent manner.